Bioorganic & Medicinal Chemistry Letters

The Tetrahedron Journal for Research at the Interface of Chemistry and Biology

Bioorganic & Medicinal Chemistry Letters - ISSN 0960-894X
Source Normalized Impact per Paper (SNIP): 0.846 Source Normalized Impact per Paper (SNIP):
SNIP measures contextual citation impact by weighting citations based on the total number of citations in a subject field.
SCImago Journal Rank (SJR): 0.843 SCImago Journal Rank (SJR):
SJR is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and a qualitative measure of the journal’s impact.
Impact Factor: 2.454 (2016) Impact Factor:
The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.
© 2017 Journal Citation Reports ® (Clarivate Analytics, 2017)
5 Year Impact Factor: 2.286 (2016) Five-Year Impact Factor:
To calculate the five year Impact Factor, citations are counted in 2016 to the previous five years and divided by the source items published in the previous five years.
© 2017 Journal Citation Reports ® (Clarivate Analytics, 2017)
Volumes: Volume 28
Issues: 24 issues
ISSN: 0960894X

Personal Subscription

Tax/VAT will be calculated at check-out

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Description

Bioorganic & Medicinal Chemistry Letters publishes research communications of outstanding significance and timeliness on topics at the interface of chemistry and biology, together with invited concise review articles. The journal publishes reports of experimental results in medicinal chemistry, chemical biology and drug discovery and design, emphasizing new and emerging advances and concepts in these fields. The journal continues to be a major forum for the first publication of new chemical entities prior to them entering clinical trials.

The Journal welcomes papers on:

  • the medicinal chemistry and associated biology (including target identification and validation) of established or new disease targets
  • the reporting of the discovery, design or optimization of potent new compounds or biological agents
  • the analysis and discussion of structure-activity relationships and pharmacological issues relevant to drug design and action using in vitro and in vivo models, including the use of computational techniques when closely linked to experimental data
  • the reporting of "first-in-class" new therapeutic compounds
  • the chemical biology or bioorganic/bioinorganic chemistry that significantly advances knowledge of a biological mechanism
  • methodological advances that are chemistry-based and which significantly impact on medicine or biology
  • the preparation and examination of biotherapeutics for the treatment of pathophysiological disease states
  • the development of materials for specific therapeutic targeting


All manuscripts will be rigorously peer-reviewed by independent experts following an initial assessment by the Editors. Please note that BMCL is not suitable for straightforward reports of incremental advances. Above all the presentation of a rational basis and a sound underlying hypothesis for the work is of particular importance, whatever its exact field.